[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100527743":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":24,"locations":30,"responsibleParty":47,"collaborators":10,"id":49,"slug":50,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":10,"eligibilityCriteria":55,"healthyVolunteers":51,"sex":56,"minAge":10,"maxAge":10,"enrollmentInfo":57,"targetDuration":10,"studyType":60,"phases":10,"briefSummary":61,"conditions":62,"keywords":10,"overallStatus":32,"whyStopped":10,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},{"fullName":5,"class":6},"Mayo Clinic","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Observational",null,"Patients attend hypertension clinic visits, undergo optional blood pressure monitoring, electrocardiograms, impedance cardiography testing and blood and urine sample collection and have medical records reviewed throughout study.",[13],"Other: Non-Interventional Study",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"Non-Interventional Study","Non-interventional study",[9],[20],{"name":21,"affiliation":22,"role":23},"Joerg Herrmann, MD","Mayo Clinic in Rochester","PRINCIPAL_INVESTIGATOR",[25],{"name":26,"role":27,"phone":28,"phoneExt":10,"email":29},"Clinical Trials Referral Office","CONTACT","855-776-0015","mayocliniccancerstudies@mayo.edu",[31],{"facility":22,"status":32,"city":33,"state":34,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"RECRUITING","Rochester","Minnesota","55905","United States","US",{"type":39,"coordinates":40},"Point",[41,42],-92.4699,44.02163,{"lat":42,"lon":41},[45,46],{"name":26,"role":27,"phone":28,"phoneExt":10,"email":29},{"name":21,"role":23,"phone":10,"phoneExt":10,"email":10},{"type":23,"investigatorFullName":21,"investigatorTitle":48,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Principal Investigator","100527743","evaluation-of-hypertension-management-and-cardiovascular-adverse-event-prevention-in-patients-with-b-cell-malignancies-undergoing-treatment-with-bruton-tyrosine-kinase-inhibitors-the-halt-study-100527743",false,"NCT06151730","Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors, the HALT Study","Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-Cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors (HALT) - A Pilot Study","Inclusion Criteria:\n\n* Patients with chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenstrom macroglobulinemia (WM), and marginal zone lymphoma (MZL), planned to begin Bruton tyrosine kinase inhibitors (BTKi) treatment or who will start a new BTKi agent after a 5-day wash out period (either as a single agent or on combination with other chemotherapies), who are willing to return to Mayo Clinic for ongoing follow-up\n\nExclusion Criteria:\n\n* Patients with known central nervous system (CNS) involvement of their B-cell malignancy","ALL",{"count":58,"type":59},100,"ESTIMATED","OBSERVATIONAL","This study evaluates the incidence and management of new and worsening high blood pressure in patients with B-cell cancers on BTKi treatment.",[63,64,65,66,67],"Chronic Lymphocytic Leukemia","Hematopoietic and Lymphoid System Neoplasm","Mantle Cell Lymphoma","Marginal Zone Lymphoma","Waldenstrom Macroglobulinemia","2026-02-24",{"date":70,"type":71},"2026-02-27","ACTUAL",{"date":73,"type":71},"2024-01-05",{"date":75,"type":59},"2026-06-30",{"name":5,"class":6},1]